Format

Send to

Choose Destination
Antivir Ther. 2009;14(8):1045-9. doi: 10.3851/IMP1428.

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?

Author information

1
Gastroenterology and Liver Unit, Di.Bi.M.I.S., University of Palermo, Palermo, Italy. craxanto@unipa.it

Abstract

The recommended treatment duration with pegylated interferon-alpha plus ribavirin for patients infected with hepatitis C virus (HCV) genotype 1 is 48 weeks. Interestingly, a subpopulation of genotype 1 patients experience rapid decreases in HCV RNA levels once treatment is initiated and attain rapid virological response, defined as undetectable HCV RNA at week 4 of therapy. Several studies have shown that these patients can be effectively treated for a 24-week period without any significant decreases in sustained virological response rates. The aim of this review was to consider the existing clinical evidence regarding the use of a 24-week treatment schedule among genotype 1 patients and to highlight the characteristics of patients most suitable for this shortened treatment schedule.

PMID:
20032534
DOI:
10.3851/IMP1428
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center